Agios Pharmaceuticals, Inc. (AGIO) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
the bull case· 4
4
disclosed supplier and customer ties in SEC filings
sec filingsedgar4
funds on file reporting a position in AGIO
n-portas of Jun 30 '26237
managers reporting a position in the latest quarterly filings
13fJun 30 '26+6.12%
change in shares held by the ten largest reporting managers
13fJun 30 '26the bear case· 3
7 of 8
recent reports where the move came in under the options implied range
earnings historyimplied vs realized0.69%
of State Street SPDR S&P Biotech ETF's assets the largest fund weight on file
n-portJun 30 '266 of 24
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Oct 29 '26 report. Not a forecast, not advice.
tall tick = annual report · 1 on record
Of the 6 companies Agios Pharmaceuticals, Inc. moves with most closely, none share its SEC classification.
Measured against 490 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
237 managers report a position worth $2.6B between them, and 29 of them hold 80% of it.
AGIO (Agios Pharmaceuticals, Inc.) has 1 disclosed suppliers and 3 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
Agios Pharmaceuticals, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
High 33.65 at 7:00 am ET, low 32.99 at 2:45 pm ET.